“…It is an oral multikinase inhibitor of vascular endothelial growth factor (VEGF) receptor (VEGFR)1-3, fibroblast growth factor receptor (FGFR)1-4, platelet-derived growth factor receptor alpha (PDGFR-α), ret proto-oncogene (RET), and KIT proto-oncogene [3][4][5]. In the phase 3 trial, lenvatinib prolonged progression-free survival (PFS; hazard ratio for progression or death, 0.21; 99 %CI, 0.14-0.31, p<0.001) by 14.7 months (lenvatinib median PFS, 8.3 months) compared with placebo (median PFS, 3.6 months) [6].…”